1-20 of 66
Josep Tabernero
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B038: Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: Findings from the PLATFORM-B study

Valentino Martelli, Joana Vidal, Maria Concepción Fernández-Rodríguez, Pilar García-Alfonso, David Páez, Joan Gibert, Jennifer Linares, Annarita Sibilio, Vicente Alonso, Maria Teresa Cano, Cristina Santos, Gema Duran, Elena Élez, José Luis Manzano, Rocio Garcia-Carbonero, Reyes Ferreiro, Ferran Losa, Estela Pineda, Javier Sastre, Auxiliadora Gomez-España, Rodrigo Toledo, Fernando Rivera, Beatriz Bellosillo, Josep Tabernero, Ramon Ramon Salazar, Enrique Aranda, Clara Montagut
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B038.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B038
Published: 13 November 2024
View article titled, Abstract B038: Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: Findings from the PLATFORM-B study
Journal Articles

Abstract PR009: Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: Findings from the PLATFORM-B study

Valentino Martelli, Joana Vidal, Maria Concepción Fernández-Rodríguez, Pilar García-Alfonso, David Páez, Joan Gibert, Jennifer Linares, Annarita Sibilio, Vicente Alonso, Maria Teresa Cano, Cristina Santos, Gema Duran, Elena Élez, José Luis Manzano, Rocio Garcia-Carbonero, Reyes Ferreiro, Ferran Losa, Estela Pineda, Javier Sastre, Auxiliadora Gomez-España, Rodrigo Toledo, Fernando Rivera, Beatriz Bellosillo, Josep Tabernero, Ramon Ramon Salazar, Enrique Aranda, Clara Montagut
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): PR009.
https://doi.org/10.1158/1557-3265.LIQBIOP24-PR009
Published: 13 November 2024
View article titled, Abstract PR009: Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: Findings from the PLATFORM-B study
Journal Articles

Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial

Petros Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K. Mellinghoff, Lipika Goyal, James J. Harding, E. Claire Dees, Rastislav Bahleda, Nilofer S. Azad, Asha Karippot, Razelle Kurzrock, Josep Tabernero, Juha Kononen, Matthew C.H. Ng, Rutika Mehta, Nataliya V. Uboha, Frédéric Bigot, Valentina Boni, Samantha E. Bowyer, Valeriy Breder, Andrés Cervantes, Nancy Chan, James M. Cleary, Mallika Dhawan, Rikke L. Eefsen, James Ewing, Donna M. Graham, Tormod K. Guren, Jin Won Kim, Krassimir Koynov, Do-Youn Oh, Rebecca Redman, Chia-Jui Yen, David Spetzler, Marie-Claude Roubaudi-Fraschini, Valerie Nicolas-Metral, Rafik Ait-Sarkouh, Claudio Zanna, Abdallah Ennaji, Anna Pokorska-Bocci, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4572–4583.
https://doi.org/10.1158/1078-0432.CCR-24-0012
Published: 15 October 2024
View article titled, Evaluating Debio 1347 in Patients with <em>FGFR</em> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Open the PDF for Evaluating Debio 1347 in Patients with <em>FGFR</em> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial in another window
Includes: Supplementary data
Journal Articles

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

Jordi Martínez-Quintanilla, Débora Cabot, Doménico Sabia, Oriol Arqués, for the PMPnet Group, Jordi Vergés, Irene Chicote, Lana Bijelic, for the PMPnet Group, Laia Cabellos, Anna M. Alcántara, Isabel Ramos, Pedro Barrios, Oriol Crusellas, Lina M. Palacio, for the PMPnet Group, Juan A. Cámara, Jorge Barriuso, for the PMPnet Group, Juan J. Jiménez, Pau Muñoz-Torres, Lara Nonell, Raquel Flores, Enzo Médico, Marcello Guaglio, for the PMPnet Group, Javier Ros, Elena Élez, Josep Tabernero, Omer Aziz, Marcello Deraco, Héctor G. Palmer, for the PMPnet Group, PMPnet Group, Chiorino Giovanna, Mazzarotto Francesco, Gariboldi Manuela, Varinelli Luca, Cavalleri Tommaso, Chakrabarty Bipasha, Nagaraju Raghavendar, Caswell Patrick, McAllister Milly
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4082–4099.
https://doi.org/10.1158/1078-0432.CCR-23-4072
Published: 13 September 2024
View article titled, Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Open the PDF for Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei in another window
Includes: Supplementary data
Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S. Rohrberg, Morten Mau-Sørensen, Debbie Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E. Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (13): 2693–2701.
https://doi.org/10.1158/1078-0432.CCR-23-3567
Published: 01 July 2024
View article titled, Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Open the PDF for Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Solange Peters, Eric Angevin, Teresa Alonso-Gordoa, Kristoffer Rohrberg, Ignacio Melero, Begoña Mellado, Jose-Luis Perez-Gracia, Josep Tabernero, Celine Adessi, Christophe Boetsch, Carl Watson, Joseph Dal Porto, David Dejardin, Christopher Del Nagro, Valeria Nicolini, Stefan Evers, Christian Klein, Barbara Leutgeb, Pavel Pisa, Eva Rossmann, José Saro, Pablo Umana, Jehad Charo, Volker Teichgräber, Neeltje Steeghs
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1630–1641.
https://doi.org/10.1158/1078-0432.CCR-23-2658
Published: 15 April 2024
View article titled, Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Open the PDF for Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer

Stefania Napolitano, Melanie Woods, Hey Min Lee, Vincenzo De Falco, Giulia Martini, Carminia Maria Della Corte, Erika Martinelli, Vincenzo Famiglietti, Davide Ciardiello, Amanda Anderson, Natalie Wall Fowlkes, Oscar Eduardo Villareal, Alexey Sorokin, Preeti Kanikarla, Olu Coker, Van Morris, Lucia Altucci, Josep Tabernero, Teresa Troiani, Fortunato Ciardiello, Scott Kopetz
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2299–2309.
https://doi.org/10.1158/1078-0432.CCR-22-3894
Published: 13 June 2023
View article titled, Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human <em>BRAF</em><sup>V600E</sup>-Mutant Colorectal Cancer
Open the PDF for Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human <em>BRAF</em><sup>V600E</sup>-Mutant Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting

Zev A. Wainberg, Jipan Xie, Adriana Valderrama, Lei Yin, Shujing Zhang, Chie-Schin Shih, Pooja Bhagia, Qianqian Gu, Kohei Shitara, Yelena Y. Janjigian, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1360–1367.
https://doi.org/10.1158/1078-0432.CCR-22-2920
Published: 03 April 2023
View article titled, Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting
Open the PDF for Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting in another window
Includes: Supplementary data
Journal Articles

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

Filippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, Simona Corso, Alessandra Raimondi, Enrico Berrino, Federica Morano, Cristina Migliore, Monica Niger, Lorenzo Castagnoli, Serenella Maria Pupa, Caterina Marchiò, Maria Di Bartolomeo, Eleonora Restuccia, Chiara Lambertini, Josep Tabernero, Silvia Giordano
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 571–580.
https://doi.org/10.1158/1078-0432.CCR-22-2533
Published: 01 February 2023
View article titled, <em>HER2</em> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Open the PDF for <em>HER2</em> Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial in another window
Includes: Supplementary data
Journal Articles

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

Joana Vidal, Maria Concepción Fernández-Rodríguez, David Casadevall, Pilar García-Alfonso, David Páez, Marta Guix, Vicente Alonso, Maria Teresa Cano, Cristina Santos, Gema Durán, Elena Elez, José Luís Manzano, Rocío Garcia-Carbonero, Reyes Ferreiro, Ferran Losa, Estela Pineda, Javier Sastre, Fernando Rivera, Beatriz Bellosillo, Josep Tabernero, Enrique Aranda, Ramon Salazar, Clara Montagut, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 379–388.
https://doi.org/10.1158/1078-0432.CCR-22-1696
Published: 17 January 2023
View article titled, Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Open the PDF for Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study in another window
Includes: Supplementary data
Journal Articles

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesús, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yáñez-Bartolomé, Florian Castet, Carles Fabregat-Franco, Carmen Escudero-Iriarte, Marta Escorihuela, Enrique J. Arenas, Cristina Bernadó-Morales, Noemí Haro, Francis J. Giles, Óscar J. Pozo, Josep M. Miquel, Paolo G. Nuciforo, Ana Vivancos, Marta Melé, Violeta Serra, Joaquín Arribas, Josep Tabernero, Sandra Peiró, Teresa Macarulla, Tian V. Tian
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 432–445.
https://doi.org/10.1158/1078-0432.CCR-22-2551
Published: 17 January 2023
View article titled, Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Open the PDF for Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation in another window
Includes: Supplementary data
Journal Articles

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Joseph Chao, Zev A. Wainberg, Z. Alexander Cao, Deepti Aurora-Garg, Julie Kobie, Razvan Cristescu, Pooja Bhagia, Sukrut Shah, Josep Tabernero, Kohei Shitara, Lucjan Wyrwicz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3489–3498.
https://doi.org/10.1158/1078-0432.CCR-22-0121
Published: 15 August 2022
View article titled, Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Open the PDF for Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study in another window
Includes: Supplementary data
Journal Articles

ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma

Helena Verdaguer, Tamara Saurí, Daniel Alejandro Acosta, Magdalena Guardiola, Alexandre Sierra, Jorge Hernando, Paulo Nuciforo, Josep M. Miquel, Cristina Molero, Sandra Peiró, Queralt Serra-Camprubí, Guillermo Villacampa, Susana Aguilar, Ana Vivancos, Josep Tabernero, Rodrigo Dienstmann, Teresa Macarulla
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1662–1671.
https://doi.org/10.1158/1078-0432.CCR-21-2384
Published: 14 April 2022
View article titled, ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
Open the PDF for ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Brasó-Maristany, Zighereda Ogbah, Mireia Parés, Marta Guzmán, Judit Grueso, Olga Rodríguez, Mafalda Oliveira, Analía Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, Aleix Prat, Rodrigo Dienstmann, Paolo Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 137–149.
https://doi.org/10.1158/1078-0432.CCR-21-1810
Published: 05 January 2022
View article titled, High <em>FGFR1–4</em> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Open the PDF for High <em>FGFR1–4</em> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer

Adam Lafferty, Alice C. O'Farrell, Giorgia Migliardi, Niraj Khemka, Andreas U. Lindner, Francesco Sassi, Eugenia R. Zanella, Manuela Salvucci, Evy Vanderheyden, Elodie Modave, Bram Boeckx, Luise Halang, Johannes Betge, Matthias P.A. Ebert, Patrick Dicker, Guillem Argilés, Josep Tabernero, Rodrigo Dienstmann, Enzo Medico, Diether Lambrechts, Andrea Bertotti, Claudio Isella, Livio Trusolino, Jochen H.M. Prehn, Annette T. Byrne
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5979–5992.
https://doi.org/10.1158/1078-0432.CCR-21-0818
Published: 01 November 2021
View article titled, Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer
Open the PDF for Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study

Yoshinori Kagawa, Elena Elez, Jesús García-Foncillas, Hideaki Bando, Hiroya Taniguchi, Ana Vivancos, Kiwamu Akagi, Ariadna García, Tadamichi Denda, Javier Ros, Tomohiro Nishina, Iosune Baraibar, Yoshito Komatsu, Davide Ciardiello, Eiji Oki, Toshihiro Kudo, Takeshi Kato, Takeharu Yamanaka, Josep Tabernero, Takayuki Yoshino
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (9): 2515–2522.
https://doi.org/10.1158/1078-0432.CCR-20-3677
Published: 01 May 2021
View article titled, Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <em>RAS</em> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study
Open the PDF for Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <em>RAS</em> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study in another window
Includes: Supplementary data
Journal Articles

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

Zev A. Wainberg, Charles S. Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Joseph Chao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (7): 1923–1931.
https://doi.org/10.1158/1078-0432.CCR-20-2980
Published: 01 April 2021
View article titled, Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Open the PDF for Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10 in another window
Journal Articles

Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

Gino M. Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Amanda Jackson, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C. T. Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Ailsa Sita-Lumsden, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Pavetha Seeva, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Charlotte Moss, Beth Russell, Josep Tabernero, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Andrea Marrari, M. Carmen Carmona-García, Neha Chopra, Carlo Tondini, Oriol Mirallas, Valeria Tovazzi, Vittoria Fotia, Claudia A. Cruz, Nadia Saoudi-Gonzalez, Eudald Felip, Lorenza Scotti, Alvin J. X. Lee, Thomas Newsom-Davis, Andrea Patriarca, Lorenza Rimassa, Armando Santoro, Alessandra Gennari, Mieke Van Hemelrijck, Nikolaos Diamantis, David J. Pinato
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6_Supplement): S01-03.
https://doi.org/10.1158/1557-3265.COVID-19-21-S01-03
Published: 15 March 2021
View article titled, Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score
Journal Articles

Abstract A19: A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC)

Sarina A. Piha-Paul, Cinta Hierro, Ignacio Matos, Valentina Boni, Noah Hahn, Rhonda Bitting, Todd Bauer, Aggarwal Rahul, Funda Meric-Bernstam, Steven Gourlay, Timothy D. Owens, Ken Brameld, Ann Neale, Richard Schwartz, Steve Murray, Sibel Ucpinar, Peter Foote, Eleni Venetsanakos, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15_Supplement): A19.
https://doi.org/10.1158/1557-3265.BLADDER19-A19
Published: 03 August 2020
View article titled, Abstract A19: A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC)
Journal Articles

Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

Martin Smoragiewicz, Alex A. Adjei, Emiliano Calvo, Josep Tabernero, Aurélien Marabelle, Christophe Massard, Jun Tang, Elisabeth G.E. de Vries, Jean-Yves Douillard, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2461–2465.
https://doi.org/10.1158/1078-0432.CCR-19-3136
Published: 01 June 2020
View article titled, Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)
Open the PDF for Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT) in another window